Topical Oxybutynin for Treatment of Hyperidrosis: Local or Systemic Effect?

Launched by SAMANTHA RODRIGUES CAMARGO NEVES DE MOURA · Oct 27, 2021

Keywords

ClinConnect Summary

The TODAY trial is studying a new treatment for excessive sweating, known as axillary hyperhidrosis, which affects the underarms. Researchers want to see if a special deodorant containing a medication called oxybutynin can help reduce sweating and if it has any side effects. This trial is currently looking for participants aged 18 to 45 who have not used any other treatments for their sweating for at least 30 days.

To join the study, you should not be allergic to oxybutynin, should not have any skin problems in your armpits, and if you're a woman who could become pregnant, you must be using birth control. Participants will apply the deodorant and be monitored for its effectiveness and safety. This is an exciting opportunity for those seeking relief from excessive sweating, and researchers are eager to see how well this new treatment works!

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients aged ≥18 years and ≤ 45 years
• • Not treated patient with another drug or treatment methodology for the disease for at least 30 days
• Exclusion Criteria:
• • Patients who are hypersensitive to oxybutynin hydrochloride.
• • Not treated patient with another drug or treatment methodology for the disease for at least 30 days
• • Patients who have menopausal symptoms
• • Patients who show signs of skin lesions in the armpit
• • Pregnancy. Women with the potential to bear children should be under contraceptive strategies and take a negative pregnancy test to be enrolled
• • Patients with COVID in the contagious phase (PCR+)